MoonLake Immunotherapeutics (MLTX)

MoonLake Immunotherapeutics is trading at $15.24, up 1.26% on the session. The 50 day average sits at $18.36 and the 200 day at $16.84, which puts the stock in a uptrend. RSI is at 32.7, which reads as weak, and MACD is bearish crossover. Volume is below average.

The nearest support is around $14.97 with resistance near $16.86, so that band frames the current range. Average daily movement is roughly $0.78, or about 5.1% of the share price, which is what any stop placement has to allow for. The overall health score of 34 out of 100 combines a trend score of 30, momentum of 20 and a risk score of 58.

MoonLake Immunotherapeutics, a clinical-stage biotechnology company, focuses on developing therapies for inflammatory skin and joint diseases. It develops Sonelokimab, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody for the treatment of inflammatory diseases in dermatology and rheumatology, as well as for hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, palmoplantar pustulosis, and psoriasis. The company was founded in 2021 and is headquartered in Zug, Switzerland.